Canna Law Blog

MARCH 21, 2022

To impose a hemp moratorium, a county must simply declare a state of emergency related to cannabis and notify the Oregon Department of Agriculture ( ODA ) of the declaration and request that the ODA deny issuance of grower licenses in order to alleviate the conditions giving rise to the declaration. In 2020, the U.S.

Hemp 94

Hemp DEA Conditions Agriculture 94

Cannabis Law Report

AUGUST 18, 2022

“We are at the beginning of a revolution in how mental health conditions are medically treated. Psychedelics present a new potential path to relief for patients who continue to struggle with mental health conditions despite conventional therapies,” he added. Tweet this. However, change appears imminent.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Canna Law Blog

JULY 14, 2023

On July 5, 2023, the FDA and FTC jointly announced six cease and desist letters to alleged delta-8 product makers. But, there’s a huge controversy about whether it can be controlled, with agencies like the DEA saying it is. You can access the letters here. You can read more about that issue here or here.

Packaging 94

Packaging Food Edibles THC 94

Cannabis Law Report

APRIL 21, 2022

MDMA is a promising psychedelic compound, currently placed by the Drug Enforcement Administration (DEA) in Schedule I of the Controlled Substances Act, that has been produced for legal research in small batches by certified laboratories.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

MAY 29, 2022

8] Spravato is derived from ketamine and categorized by DEA as a Schedule III controlled substance. 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] DEA and the Controlled Substances Act. Under the Controlled Substances Act of 1970, DEA classifies drugs into one of five schedules.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

AUGUST 6, 2021

“We’re continuing to drive cost savings and operational efficiencies across the company, and remain broadly on track to our target of $150 – $200 million in fiscal 2022- fiscal 2023,” added Mike Lee , CFO. “We Drug Enforcement Administration (the “DEA”), the U.S. First Quarter Fiscal 2022 Financial Summary. hemp industry in the U.S.,

Vaping 105

Vaping Research and Development Data Business 105

Cannabis Law Report

DECEMBER 21, 2021

It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. The company, which began trading on the OTC and Frankfurt Stock exchanges in October, has plans to open as many as 120 more clinics by 2023. Also in November, it reported positive data on its standout IND, CYB003.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

JUNE 1, 2021

Implementation of supply chain optimization well underway with network optimization and complexity reduction initiatives expected to realize our previously stated cost savings of $150 million to $200 million by the end of the first half of FY 2023. Drug Enforcement Administration (the “DEA”), the U.S.

Data 95

Data Vaping Supply Chain Business 95

Canna Law Blog

JANUARY 8, 2025

cannabis community awaits the resumption of the DEA’s administrative law hearing on rescheduling marijuana later this month, this blog will take a glimpse at the ever-dynamic global landscape of cannabis policy. Phase I, implemented in 2023, legalized cannabis cultivation clubs, home cultivation, and personal possession.

Law 123

Law Programs Cultivation Hemp 123

Veriheal

NOVEMBER 7, 2024

The Drug Enforcement Administration (DEA) announced in August that a hearing regarding the reclassification decision will take place on December 2, 2024, before an administrative law judge. Then, the DEA will review the report and draft a final ruling, factoring in all relevant information submitted during the public comment period.

DEA 97

DEA Policy Chronic Pain Marijuana 97